Multiple Myeloma Research Foundation Receives Highest Rating from Charity Navigator for Exceptional Fiscal Management


The MMRF was honored for the 15th year for outstanding stewardship of donors’ funds.

The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Navigator, America’s largest independent evaluator of charitable donations, for demonstrating strong financial health and commitment to accountability and transparency.

This is the 15th time the MMRF has earned this coveted recognition.

The coveted 4-star rating, the highest honor Charity Navigator bestows, indicates that “The Multiple Myeloma Research Foundation exceeds industry standards and outperforms most charities.” According to Charity Navigator, “this sets the MMRF apart from its peers and demonstrates to the public its trustworthiness.”

“Charity Navigator’s 4-star rating underscores our tireless commitment to accountability, efficiency and measurable results” said Paul Giusti, CEO of the MMRF. “Our commitment to our patients and donors remains focused on maximizing every dollar we invest.”

About the Multiple Myeloma Research Foundation (MMRF)

The mission of the Multiple Myeloma Research Foundation (MMRF) is to find a cure for multiple myeloma by relentlessly pursuing innovation that accelerates the development of next-generation treatments to extend the lives of patients. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c) (3) nonprofit organization, the MMRF is a world-recognized leader in cancer research. Together with its partners, the MMRF has created the only end-to-end solution in precision medicine and the single largest genomic dataset in all cancers. The MMRF continues to disrupt the industry today, as a pioneer and leader at the helm of new research efforts. Since its inception, the organization has raised over $400 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit

Related Videos
Elizabeth Aronson
Shivani Gopalsami
Donna Catamero
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Sherry Adkins Talks Primary Care Provider Communication Following CAR T-cell Therapy
Gretchen McNally Speaks to the Role of Oncology Nurses in the Opioid Epidemic
Related Content
© 2024 MJH Life Sciences

All rights reserved.